Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wise

Showing results (301-310 of 335) with videos related to

Pageof 34
Sort By:
Antimicrobial Agents and Chemotherapy|August 5, 2015
Evaluation of Gallium Citrate Formulations against a Multidrug-Resistant Strain of Klebsiella pneumoniae in a Murine Wound Model of InfectionMitchell G Thompson, Vu Truong-Le, Yonas A Alamneh, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, et al.
Journal of Virology|June 19, 2015
An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman PrimatesMegan C Wise, Natalie A Hutnick, Justin Pollara, et al.
American Journal of Human Genetics|November 13, 2001
Origins and divergence of the Roma (gypsies)D Gresham, B Morar, P A Underhill, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Frontiers in Immunology|March 13, 2023
Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression <i>in vivo</i>Nicholas J Tursi, Ziyang Xu, Michaela Helble, et al.
Annals of Internal Medicine|February 1, 1994
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyF M Wigley, R A Wise, J R Seibold, et al.
Antimicrobial Agents and Chemotherapy|December 18, 2013
Validation of a novel murine wound model of Acinetobacter baumannii infectionMitchell G Thompson, Chad C Black, Rebecca L Pavlicek, et al.
Pageof 34

Showing results (301-310 of 335) with videos related to

Sort By:
Pageof 34
Antimicrobial Agents and Chemotherapy|August 5, 2015
Evaluation of Gallium Citrate Formulations against a Multidrug-Resistant Strain of Klebsiella pneumoniae in a Murine Wound Model of InfectionMitchell G Thompson, Vu Truong-Le, Yonas A Alamneh, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, et al.
Journal of Virology|June 19, 2015
An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman PrimatesMegan C Wise, Natalie A Hutnick, Justin Pollara, et al.
American Journal of Human Genetics|November 13, 2001
Origins and divergence of the Roma (gypsies)D Gresham, B Morar, P A Underhill, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Frontiers in Immunology|March 13, 2023
Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression <i>in vivo</i>Nicholas J Tursi, Ziyang Xu, Michaela Helble, et al.
Annals of Internal Medicine|February 1, 1994
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyF M Wigley, R A Wise, J R Seibold, et al.
Antimicrobial Agents and Chemotherapy|December 18, 2013
Validation of a novel murine wound model of Acinetobacter baumannii infectionMitchell G Thompson, Chad C Black, Rebecca L Pavlicek, et al.
Pageof 34